ibuprofen
ibuprofen
Overview
Ibuprofen is a propionic acid-derived non-steroidal anti-inflammatory drug (NSAID) widely used for its analgesic, antipyretic, and anti-inflammatory properties. It exerts its pharmacological effects primarily through reversible inhibition of cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the biosynthesis of prostaglandins and thromboxanes involved in pain signaling, fever induction, and inflammatory cascades. Available in numerous formulations — including immediate-release tablets, lysinate salts, and sustained-release compositions — ibuprofen occupies a central role in both prescription and over-the-counter (OTC) pain and fever management, with non-prescription use typically capped at a maximum daily dose of 1,200 mg. Beyond its classical analgesic indication, ibuprofen has attracted sustained scientific interest for its potential utility in oncology, infectious disease, drug delivery, and environmental monitoring, positioning it as a molecularly versatile compound across multiple biomedical domains.
As a small-molecule NSAID, ibuprofen belongs to the same pharmacological class as indomethacin, naproxen, Diclofenac, ketoprofen, and mefenamic acid — agents with which it is frequently compared in pharmacokinetic, ecological, and clinical studies. Its broad tissue distribution and relatively short half-life make formulation optimization an active area of pharmaceutical research, while its widespread consumption and incomplete environmental metabolism have established it as a prototypical pharmaceutical micropollutant of global concern.
Focus of Latest Publications
Recent publications on ibuprofen have focused largely on formulation optimization, delivery strategies, and repurposing beyond conventional analgesic use. Two pharmacokinetic studies evaluated modified-release oral products designed to reduce dosing frequency. A biphasic 400 mg immediate-release/sustained-release tablet showed bioequivalent total and peak exposure to reference immediate-release ibuprofen after single dosing, and equivalent steady-state exposure after repeated dosing, while food did not significantly affect absorption. In a related in vivo and virtual pharmacokinetic analysis, an immediate-release/sustained-release bi-layer tablet maintained plasma concentrations above predefined therapeutic thresholds for longer than immediate-release formulations, supporting prolonged pain and fever relief with fewer daily doses.
Several studies examined ibuprofen in advanced dosage forms and manufacturing platforms. Semi-solid extrusion 3D printing using milk formula as the main excipient produced pediatric chewable dosage forms containing ibuprofen, with dose accuracy scaling linearly with print weight and dissolution showing modestly improved ibuprofen release from the milk matrix. In another manufacturing-focused study, membrane percrystallization was used to crystallize ibuprofen microcrystals with high yield, stable Form I purity, low residual solvent and moisture, and improved flowability compared with commercial ibuprofen, indicating potential for integrated crystallization and particle engineering.
Ibuprofen was also investigated in combination therapies and local delivery systems. In a rat model of Staphylococcus aureus-induced keratitis, eye drops containing levofloxacin plus ibuprofen produced the lowest expression of inflammatory mediators, metalloproteinases, corneal angiogenesis markers, and Bax, with histology showing the best therapeutic outcomes among the tested groups. For osteoarthritis, ibuprofen-loaded mesoporous silica nanoparticles were incorporated into injectable thermoresponsive hydrogels for intra-articular delivery; these systems enabled rapid ibuprofen release, sustained resveratrol release, and in a papain-induced rat model reduced inflammatory cytokines including interleukin-6, lowered oxidative stress markers, and improved joint architecture, with the MCM-41-based formulation performing better than the SBA-15-based system.
Beyond therapeutic delivery, ibuprofen has appeared in studies of analytical methods and broader biomedical screening. An eco-friendly HPTLC method was validated for simultaneous determination of erdosteine, ibuprofen, and pseudoephedrine in a pharmaceutical combination used for upper respiratory tract infection symptoms. In cancer research, connectivity map screening identified ibuprofen as a candidate that could enhance osimertinib activity and help overcome resistance in patient-derived lung cancer organoids and TKI-resistant cell models.